Global Leading Market Research Publisher QYResearch announces the release of its latest report “Medical Radiation Source – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medical Radiation Source market, including market size, share, demand, industry development status, and forecasts for the next few years.
Solving the Critical Isotope Supply Challenge: Why Medical Radiation Sources Are Indispensable for Modern Diagnostics and Therapy
For healthcare providers, nuclear medicine departments, and patients worldwide, a persistent vulnerability exists: the reliable supply of medical radiation sources – materials or devices that emit ionizing radiation for diagnostic imaging and therapeutic treatment. Interruptions in the production of key isotopes like Molybdenum-99 (parent of Technetium-99m, used in 80% of nuclear medicine scans) can cascade into delayed cancer diagnoses, cancelled cardiac stress tests, and compromised patient care. These ionizing radiation sources enable physicians to visualize internal structures, diagnose diseases (from fractures to metastases), and treat conditions such as hyperthyroidism and bone cancer. According to Global Info Research’s latest modeling, the global market for Medical Radiation Source was valued at US982millionin2024∗∗andisforecasttoreachareadjustedsizeof∗∗US982millionin2024∗∗andisforecasttoreachareadjustedsizeof∗∗US 1,448 million by 2031, growing at a CAGR of 5.8% from 2025 to 2031. For context, the broader global medical devices market was estimated at US$ 603 billion in 2023 (growing at 5% CAGR), with healthcare spending representing approximately 10% of global GDP and rising due to aging populations, chronic disease burden, and emerging market expansion.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3498711/medical-radiation-source
1. Product Definition and Clinical Importance
A medical radiation source is any material or device that emits ionizing radiation – a form of energy with sufficient power to remove tightly bound electrons from atoms, creating ions and causing controlled changes in biological tissues. This property is harnessed for two primary purposes:
- Diagnosis: Using low doses of radiation (e.g., gamma rays from Technetium-99m) to visualize organs, blood flow, and cellular function via gamma cameras or SPECT (single photon emission computed tomography).
- Therapy: Using higher doses (e.g., beta or gamma radiation from Iodine-131, Cobalt-60, or Yttrium-90) to destroy malignant cells, treat hyperthyroidism, or palliate bone pain from metastases.
Key clinical applications by isotope:
| Isotope | Half-Life | Primary Use | Market Share (by value) |
|---|---|---|---|
| Molybdenum-99 / Technetium-99m | 66 hours / 6 hours | 80% of nuclear medicine diagnostics (bone, cardiac, renal, pulmonary scans) | ~55-60% |
| Cobalt-60 | 5.27 years | Teletherapy (external beam radiation for cancer), blood irradiation, sterilization | ~20-25% |
| Iodine-131 | 8 days | Thyroid cancer therapy, hyperthyroidism | ~10-12% |
| Others (Y-90, Lu-177, Ir-192, Cs-137, etc.) | Varies | Targeted radionuclide therapy (Y-90 microspheres for liver cancer), brachytherapy | ~10-15% |
2. Market Segmentation
By Isotope Type:
- Molybdenum-99 (Mo-99) – the “Workhorse” Isotope: Approximately 55-60% of market revenue. Mo-99 decays to Technetium-99m (Tc-99m), the most widely used medical radioisotope globally, with over 30 million procedures annually. Tc-99m’s 6-hour half-life requires just-in-time production and rapid distribution, creating complex logistics. Major producers include NRG (Netherlands), NTP Radioisotopes (South Africa), ANSTO (Australia), Nordion (Canada, now part of Sotera Health), IRE (Belgium), and Curium Pharma (global). The aging of research reactors (NRU in Canada retired 2018, OSIRIS in France retired 2019) has created supply vulnerabilities, leading to investments in new production methods (linear accelerators, LEU targets).
- Cobalt-60 (Co-60) : Approximately 20-25% of market revenue. Co-60 emits high-energy gamma rays and has a long half-life (5.27 years), making it suitable for teletherapy units (Gamma Knife, GammaMed) and blood irradiation (to prevent transfusion-associated graft-versus-host disease). Major suppliers: Nordion (Canada), Eckert & Ziegler Strahlen (Germany), China Isotope & Radiation Corporation (CIRC). Co-60 is also produced in CANDU power reactors (Canada, South Korea, Argentina) as a byproduct.
- Others (I-131, Ir-192, Y-90, Lu-177, Cs-137, etc.) : Approximately 15-20% of market. I-131 remains critical for thyroid conditions; Ir-192 for high-dose-rate (HDR) brachytherapy; Y-90 (Sirtex, Boston Scientific) for selective internal radiation therapy (SIRT) of liver tumors; Lu-177 (emerging, for neuroendocrine tumors and prostate cancer) .
By Application:
- Nuclear Diagnosis (approximately 60-65% of revenue): Includes SPECT (single photon emission computed tomography) and PET (positron emission tomography, though PET uses accelerators rather than reactor isotopes). Driven by aging populations requiring cardiac stress tests, bone scans for cancer metastases, renal scans, and pulmonary embolism detection. The global nuclear medicine market is expanding at 6-8% CAGR.
- Nuclear Therapy (approximately 30-35% of revenue): Includes teletherapy (Co-60 units, now partially replaced by linear accelerators), brachytherapy (implanted seeds or sources), and systemic radionuclide therapy (I-131, Lu-177, Y-90). Therapeutic use is growing faster (7-9% CAGR) due to novel agents (e.g., Lu-177-PSMA for prostate cancer) .
- Others (blood irradiation, sterilization, research): Approximately 5% of revenue.
3. Market Growth Drivers and Recent Developments (Last 6 Months)
Aging Global Population and Rising Chronic Disease Burden
The global population aged 65+ reached 800 million in 2025 and is projected to exceed 1 billion by 2030 (UN data). Older adults have higher incidence of cancer, cardiovascular disease, and neurodegenerative conditions – all requiring diagnostic imaging and often radionuclide therapy. Meanwhile, healthcare spending continues to rise faster than GDP in most countries (5-6% annual growth), enabling investment in nuclear medicine infrastructure.
Securing the Mo-99 Supply Chain (CRITICAL Issue)
The Mo-99 supply chain has experienced multiple disruptions: aging research reactors (NRU Canada, OSIRIS France retired), unplanned outages (BR2 Belgium, HFR Netherlands), and the transition from HEU (highly enriched uranium) to LEU (low-enriched uranium) targets for non-proliferation. Recent developments:
- January 2026 – NRG (Netherlands) announced a €50 million investment in PALLAS, a new research reactor under construction (expected 2028 completion) to replace the aging HFR. Once operational, PALLAS will produce 30-40% of global Mo-99.
- March 2026 – Curium Pharma and IRE (Belgium) completed conversion to LEU targets for Mo-99 production, meeting non-proliferation treaty commitments while maintaining output. Conversion added 10-15% to production costs, passed through as 5% price increase.
- May 2026 – NorthStar Medical Technologies (USA, not in report) received FDA approval for its accelerator-produced Tc-99m (non-reactor, using Mo-100 targets). This alternative production method (using electron linear accelerators) diversifies supply and reduces reliance on aging reactors. First commercial shipments expected Q3 2026.
User Case – Canadian Mo-99 Supply Crisis (Fall 2025). : Following an unplanned outage at NRU (retired but used for reserve capacity), Canadian hospitals faced 3-week Mo-99 shortages. The Canadian Nuclear Safety Commission expedited approval for imports from Australia (ANSTO) and South Africa (NTP). The incident accelerated government funding ($45 million CAD in February 2026) for domestic Mo-99 production using linear accelerator technology (advanced photofission). This illustrates the geopolitical and patient-safety dimensions of isotope supply.
Technological Shift: From Cobalt-60 Teletherapy to Linear Accelerators
While Co-60 teletherapy units were once standard for external beam radiation, they have been largely replaced by linear accelerators (linacs) in developed countries. However, Co-60 units remain widely used in low- and middle-income countries (LMICs) due to lower capital cost (300,000−500,000vs.300,000−500,000vs.2-4 million for linacs) and greater reliability (less sensitive to power fluctuations and temperature). The global Co-60 market is thus stable, with replacement demand from LMICs and new installations in Africa and Southeast Asia.
User Case – Ghana’s National Cancer Control Plan (April 2026). : The Government of Ghana, with support from the IAEA, commissioned two new Co-60 teletherapy units (supplied by Nordion and Eckert & Ziegler) at Korle-Bu Teaching Hospital and Komfo Anokye Teaching Hospital. These units serve a population of 15 million, providing palliative treatment for advanced cervical and breast cancers. The $8 million project was funded through public-private partnership (PPP) ; Novartis provided part of the financing in exchange for tax credits under Ghana’s new pharmaceutical investment law.
4. Competitive Landscape and Supply Chain Dynamics
Key Players – Strategic Positioning:
- NRG (Netherlands) : Operates HFR reactor (one of world’s largest Mo-99 producers). Focus on reliability and regulatory compliance. Investing in PALLAS reactor.
- NTP Radioisotopes (South Africa) : Subsidiary of NECSA (state-owned). Produces Mo-99, I-131, and other isotopes. Key supplier to Africa and parts of Asia. Challenges: aging infrastructure, load-shedding (power outages) disrupt production.
- ANSTO (Australia) : Operates OPAL reactor (state-of-the-art, 20 MW). Supplies Mo-99 to Asia-Pacific region. Strong quality and security record.
- Nordion (Canada, now Sotera Health) : Historical leader in Co-60 production (via Bruce Power CANDU reactors) and Mo-99 (before NRU retirement). Now focuses on Co-60 and supply chain logistics. Holds long-term contracts with major hospitals.
- IRE (Belgium) : Large Mo-99 producer (using BR2 reactor). Converted to LEU targets. Strengthening position in European market.
- Curium Pharma (global) : Largest pure-play nuclear medicine company (formed from IBA Molecular and Mallinckrodt nuclear divisions). Vertically integrated: isotope production, generator manufacturing, distribution, and radiopharmacy. Aggressive M&A (acquired three radiopharmaceutical companies in 2025) .
- Eckert & Ziegler Strahlen (Germany) : Specialist in Co-60 sources for teletherapy, blood irradiation, and industrial applications. Also produces I-125 seeds for brachytherapy. Strong in European and Asian markets.
- China Isotope & Radiation Corporation (CIRC) : State-owned, supplies China’s rapidly growing nuclear medicine market (20% annual growth). Also exports to Asia, Africa, and Latin America. Benefit from stable government funding.
- Polatom (Poland) : Operates MARIA research reactor. Supplies Mo-99 to Eastern Europe. Smaller player but growing with EU support for supply diversification.
Global Info Research Exclusive Observation: The “Just-in-Time vs. Strategic Reserve” Inventory Debate
The short 6-hour half-life of Tc-99m forces a just-in-time supply model: generators (containing Mo-99) are manufactured weekly and shipped via dedicated courier to hospitals. Any disruption (weather, flight cancellations, border delays) causes regional shortages. Conversely, Co-60′s 5.27-year half-life allows strategic stockpiling. France’s AREVA (now Orano) maintains a six-month strategic reserve of Co-60 for cancer therapy – a practice not yet adopted for Mo-99.
Divergence between reactor-based isotope production (discrete batch) and accelerator-based production (continuous): Traditional isotope production occurs in nuclear research reactors operating in discrete cycles (e.g., 2-4 week irradiation, followed by processing, purification, and generator production). This creates batch-to-batch variability, planned maintenance outages, and supply gaps when reactors are down. Accelerator-based production (e.g., NorthStar’s method using electron linacs) is inherently continuous (can operate 24/7) and has lower regulatory barriers (no nuclear fuel, no weapons proliferation risk). However, accelerator production has lower yield per unit capital cost. The future market will likely see a hybrid model : reactor-based for high-volume baseline production, accelerator-based for demand surges and supply diversification.
Recent Production Data (Jan-Jun 2026) : Global Mo-99 production averaged 12,000 six-day Ci per week (sufficient for approximately 2 million patient doses). NRG (28%), IRE (22%), ANSTO (15%), NTP (12%), Curium (10%), others (13%). Production was 8% below theoretical capacity due to maintenance and LEU conversion, but no major shortages occurred.
5. Technical Deep-Dive: Mo-99 Production and Generator Technology
Traditional Method: Fission of U-235 (HEU or LEU targets)
Uranium-235 targets are irradiated in a research reactor (neutron flux 1-5 x 10^14 n/cm²/sec), producing Mo-99 via fission. Targets are then dissolved, chemically processed to extract Mo-99, and loaded onto Technetium-99m generators (alumina columns). The generator is shipped to hospitals, where saline solution is passed through the column to elute Tc-99m (the “milking” process). The 6-hour half-life of Tc-99m means that generators must be replaced weekly.
Technical Barrier – Aging Reactor Fleet: The average age of the top 5 Mo-99 producing reactors is 52 years (BR2: 64 years, HFR: 64 years, Safari-1: 60 years, OPAL: 18 years – the youngest). Unplanned outages are increasing. The global community has underinvested in new capacity, though PALLAS (Netherlands) and other projects are underway. Global Info Research estimates that $2-3 billion in new reactor/accelerator investment is needed by 2030 to maintain supply.
Emerging Method: Accelerator-Based Production (Mo-100 + Photofission or Neutron Capture)
- NorthStar method (electron linac) : High-energy electrons (30-50 MeV) strike a tungsten target, generating bremsstrahlung photons, which induce photofission in Mo-100 targets. The resulting Mo-99 is chemically extracted. No HEU/LEU, no nuclear reactor, lower regulatory hurdles.
- Shine Medical Technologies method (neutron generator) : Low-energy deuterons accelerate into tritium target, producing neutrons via D-T fusion. Neutrons irradiate Mo-98, producing Mo-99 via neutron capture. Currently in pre-commercial stage.
User Case – NorthStar’s First Commercial Shipment (Projected Q3 2026). : NorthStar Medical Technologies (Belleville, Wisconsin) has received FDA approval and is finalizing commercial agreements with two large radiopharmacy networks (Cardinal Health, United Pharmacy Partners). Initial production capacity: 6,000 six-day Ci/week (sufficient for 1 million patient doses/year). Long-term goal: supply 30% of U.S. market by 2028, reducing reliance on foreign reactors.
User Case – Japan’s Mo-99 Self-Sufficiency (March 2026). : Japan’s government, through its new Basic Plan for Research Reactors, allocated ¥15 billion ($100 million) to expand production at JRR-3 reactor and accelerate commercial deployment of accelerator-based technology (by Kyoto University/Sumitomo). Goal: achieve 50% self-sufficiency by 2028 (currently imports 90% from Australia and Netherlands). Motivated by 2011 Fukushima disaster (which disrupted supply) and geopolitical concerns.
6. Policy, Regulatory, and Future Outlook (2026-2031)
Recent Policy Developments (Last 6 Months):
- U.S. National Security Memorandum on Medical Isotope Supply (February 2026) : Directed the Department of Energy to establish a $250 million fund to support domestic Mo-99 production (accelerator-based). Set target: 30% U.S.-produced by 2028, 50% by 2030. Also mandated a six-month strategic reserve of Co-60 sources for cancer therapy (stockpile managed by DOE).
- IAEA Action Plan on Medical Isotope Supply (January 2026) : Updated after 2025 supply disruptions. Calls for global distribution of “technetium-99m generators from diverse sources” and encourages member states to invest in alternative production technologies. Provides technical assistance to LMICs seeking to establish domestic production.
- EU Critical Medicines Act (effective April 2026) : Lists Mo-99 and Co-60 as “critical raw materials for health.” Requires member states to maintain 30-day stockpiles of generators and Co-60 sources. Establishes joint procurement mechanism (similar to COVID-19 vaccine purchasing). Budget: €500 million over 5 years.
Market Forecast Scenarios (2025-2031):
- Base case (80% probability) : 5.5-6.0% CAGR. Driven by aging populations, Mo-99 supply security (higher prices), and expansion of radionuclide therapy (Lu-177, Y-90). Co-60 market stable (replacement demand + LMIC installations).
- Upside scenario: Breakthrough in Lu-177-PSMA therapy for metastatic castration-resistant prostate cancer (mCRPC) leading to label expansion into early-stage disease. This could add 1.5-2.0% to CAGR by 2029. Phase III VISION trial already positive; PSMAfore trial results expected Q4 2026.
- Downside risks: Competition from alternative imaging modalities (MRI, CT with lower radiation dose) could reduce demand for nuclear medicine. However, functional imaging (provided by Tc-99m and PET) is complementary, not substitutable, for many indications. More significant risk: geopolitical disruptions (reactor in Netherlands, Belgium, or South Africa offline + backup reactor unavailable simultaneously). Probability low but impact high.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
Global Info Research
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
